ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non-Hodgkin Lymphoma (iNHL)
EudraCT number 2019-001381-14
Protocol number VS-0145-229
Sponsor Secura Bio, Inc., 1195 Village Center cir, Suite 128, Las Vegas, NV 89134, United States of America
Indications Hemato-oncology
Diagnosis Non-Hodgkin Lymphoma
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2019
Date of approval by Institute (SÚKL) 31.10.2019
Date of approval by EC 4.9.2019
Date of initiation CT in ČR 8.7.2020
Date of ending CT in ČR
Sites Fakultní nemocnice Hradec Králové,IV. interní hematologická klinika,Sokolská 581,Hradec Králové,500 05
Fakultní nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790/5,Ostrava-Poruba,708 52
Všeobecná fakultní nemocnice v Praze,I. Interní klinika - Klinika hematologie VFN a 1.LF UK v Praze,U Nemocnice 2,Praha 2,128 08

‹‹ Back to list